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ABSTRACT 
 
Taurolidine is an experimental anti-bacterial and anti-endotoxic compound whose clinical 
utility as an anti-tumor agent is being investigated in human clinical trials.  Taurolidine in 
aqeous solution exists in equilibrium with taurultam.  Taurultam is subsequently 
transformed to taurinamide.  The pharmacokinetic profiles of these metabolites are not 
well established.  In this study, eighteen healthy volunteers were administered 5.0 g of 
taurolidine in 250 mL of 5% polyvinylpyrrolidone in water over either 2, 1, or 0.5 hour 
by intravenous infusion in a parallel group design.  All subjects noted discomfort at the 
infusion site, though there were no serious adverse events.  Tmax generally occurred at the 
end of infusion for taurinamide while that of taurultam was reached before completion of 
infusion.  The taurolidine metabolite taurultam demonstrated a shorter half-life and lower 
systemic exposure than taurinamide.  Shortening of infusion duration increased the Cmax 
and AUC of taurultam.  Changes in infusion rate did not substantially change the 
pharmacokinetic parameters of taurinamide.   
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INTRODUCTION 
 
Taurolidine [TRD] is a small dimeric molecule with bactericidal properties against a 
broad spectrum of bacteria ranging from anaerobic to aerobic species.1, 2, 3  Tauroldine’s 
mechanism of action as an antibiotic agent is associated with a chemical reaction between 
the active TRD metabolites, taurultam [TRT] and taurinamide [TRM] with the structures 
of bacterial wall.3, 6  In addition, TRD exhibits the ability to neutralize bacterial 
endotoxins, exotoxins and lipopolysaccharides.7, 8, 9 The most widespread clinical 
application of TRD at present is as a catheter lock solution to reduce the incidence of 
vascular access-associated blood stream infections.  Other clinical applications have 
included peritoneal lavage for prophylaxis against post-operational bacterial infections in 
patients with established peritonitis following elective colorectal surgeries, and as an anti-
endotoxic agent in patients with systemic inflammatory response syndrome.2, 3, 10   
 
TRD has also been investigated extensively as an experimental anti-neoplastic agent in in 
vitro and in vivo studies.11, 12, 13, 14  It appears to have a direct effect on various tumor cell 
lines with a consecutive inhibition in cell growth.12, 15  Preclinical investigations have 
suggested activity against colon, ovarian, and prostate cancer, as well as melanoma, and 
mesothelioma.  Of significance, intra-peritoneal and systemic application of TRD 
resulted in a reduction of intra- and extra-peritoneal metastases in rodent models, 
suggesting utility as a chemopreventive agent against metastases.11, 16  Indeed, 
prophylactic, intra-operative peritoneal lavage with TRD for prevention of metastatic 
diseases has been successfully applied, while intravenous administration of the agent as 
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the primary treatment of poorly managed malignancies has been currently investigated in 
clinical trials.17, 18 
 
Despite administration to over 13,000 patients, the pharmacokinetics of TRD metabolites 
has not been comprehensively characterized in humans.  TRD in aqueous solution 
undergoes rapid conversion to TRT, with smaller amounts of hydroxymethyltaurultam.  
TRT is subsequently converted to TRM [Figure 1].19, 20 Because of these metabolic 
characteristics, the TRD metabolites are more important pharmacokinetic markers than 
the parent compound in studying its pharmacodynamic properties including antibacterial 
and anti-neoplastic repertoire.  In this study, the pharmacokinetics of TRD metabolites 
was investigated in healthy volunteers following intravenous administration of TRD 
solution. 
 
METHODS 
 
Subjects 
Healthy male or female subjects between the ages of 18 and 45 years, between 45 and 
100 kg and within 20% of ideal body weight range for body frame, were eligible to 
participate in the present study.  The use of prescription medications and tobacco were 
exclusion criteria.  The study was approved by the institutional review board of Thomas 
Jefferson University.  All subjects gave written informed consent to participate prior to 
undergoing any study-related procedures. 
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Study Design 
This was an open labeled, three-arm, single dose, parallel study that compared the 
pharmacokinetics and safety of [1] 5.0 gram [g] taurolidine intravenous infusion over 2 
hours [h],  [2] 5.0 g taurolidine intravenous infusion over 1 h and [3] 5.0 g taurolidine 
intravenous infusion over 0.5 h.  Taurolidine was prepared as a 2% solution in 250 ml of 
water and 5% polyvinylpyrrolidone [Kollidon® 17, BASF].  Healthy volunteers 
underwent a screening visit within three weeks of drug administration.  Each subject was 
admitted to the Clinical Pharmacology Research Unit of Thomas Jefferson University 
Hospital the day before each treatment.  Following an overnight fast, they received one of 
the three treatments.  Clinical laboratory tests, electrocardiogram, and vital signs were 
performed at baseline and at specified intervals post dose.  Twenty-four hours after each 
treatment, subjects were discharged from the unit. 
 
Collection and determination of analyte concentrations 
Blood was drawn for TRT and TRM pharmacokinetics predose, and at 5, 15, 30, 45 min, 
and 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 18 and 24 hours postdose.  Time zero was the beginning 
of intravenous infusion.  Blood samples were collected in sodium heparin-containing 
tubes, and immediately [within 40 seconds] mixed with the derivatizing agent 9-
fluorenylmethyl-chlorformate [FMOC-CI] in an acetonitrile and pseudoephedrine 
processing solution.  Samples were incubated at room temperature between 30-45 
minutes, followed by freezing at -200C.  Analysis was performed by Kansas City 
Analytical Services [Shawnee, KS] using a validated high performance liquid 
chromatography [HPLC] method.  In addition to the pre-column derivatization, the 
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method consisted of liquid-liquid extraction, gradient HPLC separation, and fluorescence 
detection using a 260 nm excitation/340 nm emission cut-off filter.  The analytic range 
for TRT was 20 to 1000 µM and 20 to 900 µM for TRM.  At the time of analysis, 
samples were thawed, combined with additional derivatizing reagent FMOC-Cl, and 
respective TRT and TRM internal standards.  The samples were allowed to react for 10 
min, quenched with the addition of taurine, and extracted into an organic solvent.  The 
extracts were reconstituted in mobile phase and subjected to reverse phase HPLC using a 
5 µ ODS column.  The analytes were detected using fluorescence detection and system 
calibration was accomplished by weighted linear least-square regression of the weight-
normalized peak height ratio [analyte/internal standard] vs. the nominal concentration of 
analyte.  During validation, the correlation coefficient [r] was ≥0.995 for TRT and 
≥0.997 for TRM, respectively.  The precision for this assay was 1.3 to 15.95% CV for 
TRT and 2.3 to 8.5% for TRM, respectively, while accuracy [% of recovery] was 94.9 to 
116.3% for TRT and 102.1 to 114.6% for TRM. 
 
Pharmacokinetic Analysis 
The apparent clearance [Cl] and volume of distribution [Vd] of TRD metabolites, TRT 
and TRM, following intravenous infusion of TRD, along with the terminal elimination 
rate constant [λz], and corresponding half-life [t1/2], maximum concentration [Cmax], time 
to maximum concentration [Tmax], observed area under the curve [AUC0-24] and area 
under the curve extrapolated to infinity [AUC0-∞], were estimated based on whole blood 
concentration [µg/mL] versus time [h] data using non-compartmental methods 
[WinNonlin 5.01 software; Pharsight, Mountain View, CA]. 
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RESULTS 
 
Demographics 
Eighteen healthy volunteers [16 males and 2 females] with a mean age of 30.7 [range 21 
to 42], participated in the study.  Ten subjects were black, 6 white, one Hispanic and one 
subject was self-described as mixed race.  Detailed demographic data is summarized in 
Table 1.  All subjects completed the study.  
 
Pharmacokinetics 
The present study compared the pharmacokinetics of TRD metabolites over 3 different 
durations of intravenous infusion with parent compound TRD [Tables 2, 3; Figure 2].  
Data from the subject in the one hour infusion group who had his infusion rate decreased 
on account of infusional burning was not included in PK analysis.  Estimated clearance 
and volume of distribution were calculated using the assumption of a 5 gm dose of parent 
compound.  The mean clearance (L/hr) was 124.6 (SD 35.7) for TRT and 16.5 (SD 3.2) 
for TRM.  The mean volume of distribution (L) was 252.9 (SD 132.9) for TRT and 155.1 
(SD 32.5) for TRM.  Each metabolite is proportional to parent on a molar basis but 
involves the liberation of water, so the clearance and volume of distribution presented are 
likely overestimates of actual values.  The AUC and Cmax of TRT increased, and Cl 
decreased with decreasing infusion time, suggesting a saturable elimination process.  
TRM lacked such changes and with the exception of Tmax, pharmacokinetic parameters 
were comparable across different durations of infusion.  Due to the limited number of 
time points during the first hour after the initiation of intravenous infusion, Tmax values 
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should be considered estimates.  Maximum concentrations were reached sooner for TRT 
in the order of 0.5 hr-infusion < 1 hr-infusion < 2 hr-infusion (p = 0.0017).  The Tmax for 
TRM occurred essentially at the end of infusion while that of TRT appeared generally to 
be achieved before completing the infusion (p < 0.05).   
 
Safety 
Safety data on all subjects in the trial is reported.  There were no serious adverse effects 
associated with the administration of taurolidine infusions.  No hypotension was noted 
during drug infusion.  All subjects noted burning at the infusion site. Five were graded as 
mild, twelve as moderate, and one subject in the one hour infusion rate group had severe 
buring that required a decrease in the rate of infusion.  Seven subjects also described a 
numbness or soreness in the infusion arm or shoulder.  Four episodes were ranked as mild 
and three as moderate.  Infusion-related symptoms began within one minute of onset and 
generally ceased at the end of infusion.  Four subjects had mild erythematous streaking at 
the site of the IV, which also resolved quickly after the end of infusion.  Five subjects had 
facial flushing, of which four were mild and one was moderate.  Four of the flushing 
episodes took place in the 0.5 hr-infusion group and one in the 1 hr group.  Other adverse 
events included single occurrences of headache, epistaxis, and nausea.  There were no 
clinically significant abnormalities in vital signs, electrocardiograms, and clinical 
laboratory tests except one subject with a single elevated prothrombin time value felt to 
be possibly related to study drug. 
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DISCUSSION 
 
TRD was synthesized in 1970s and was originally used as an antibiotic in the 
prophylactic treatment of intraperitoneal bacterial infections in patients with established 
peritonitis.1, 2, 3  The utility of taurolidine as an anti-tumor agent has been investigated 
extensively recently.17  Although intra-operative peritoneal lavage of TRD for 
prophylactic therapies either as an antibiotic or as an anti-tumor agent against metastatic 
diseases has been administered clinically, the pharmacokinetics of TRD metabolites after 
intravenous administration was not well established.  Pharmacokinetic characterization of 
taurolidine metabolites had been hampered by the rapid in vivo conversion of TRT to 
TRM.  Key to the present investigation was the development of a sensitive assay and 
careful attention to derivatizing samples immediately after collection.   
 
Previous analytical studies on animal specimens revealed that TRD exists in equilibrium 
with TRT, which further reversibly converts to TRM and other degradation products 
[Figure 1].19, 20 In a clinical investigation, Erb et al19 reported a biphasic elimination of 
TRT in a model-based analysis after IV administration of 1 gram over one hour in six 
subjects using a different analytic method.  Beta t1/2 was reported as 2.2 h and Vd was 162 
± 93 L, which is comparable to the findings reported here [Table 2].  In the present study, 
intravenous infusion of 5.0 g of taurolidine resulted in a smaller AUC for TRT than for 
TRM and, conversely, a larger Cl for the former than for the latter [Table 2 and 3].  These 
findings demonstrate that TRT is an unstable and short-lived metabolite.  Prior 
investigations revealed that the antibiotic action of TRD appeared to be related to action 
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of active metabolites methylol TRT and methylol TRM [Figure 1] on bacterial cell 
walls,2, 21 while the antitumor activities were likely due to its proapoptotic and 
antiangiogenic effects on tumor cells.17, 18  The present study did not include 
pharmacodynamic measures to define mechanisms of action of each metabolite.   
 
TRD not only acts as an antibacterial agent to suppress infection but also prevents the 
growth and spread of tumor cells.  In oncology patients, intravenous infusions were 
reported of up to 20 g/day (1,000 ml of 2% TRD), which were ~4 times more than that 
examined in the present study, and few clinically relevant drug adverse effects were 
observed.15, 17, 22 Anti-tumor activity has been noted preclinically at micromolar 
concentrations in many tumor cell lines.18  These concentrations were demonstrated for 
both metabolites in the present study.  The PK parameters generated in this study will 
assist in the rational dose and infusion interval selection in future human clinical trials. 
 
Finally, safety data reported here in healthy adults indicate that local reactions including 
burning at the infusion site, numbness or soreness of the infusion arm and erythematous 
streaking at the IV site were the most common adverse effects associated with 
intravenous TRD administration.  Systemic clinically relevant drug toxicities were 
minimal in this study, in accordance with the other prior clinical investigations related to 
the low toxicity of this agent.17   
 
In summary, there was no serious adverse events occurred in intravenous administrations 
of 5 g TRD 2% solution in healthy subjects.  Local irritation at infusion sites was 
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observed although all subjects completed the infusion.  The TRD metabolite TRT 
demonstrated a shorter half-life and systemic exposure than TRM.  Shortening of 
infusion duration increased the Cmax and AUC of TRT relative to that of TRM.  
Characterization of metabolite pharmacokinetics will assist in the further clinical 
development of TRD. 
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Table 1: Demographic characteristics of research subjects 
 
 
Group 2-h infusion 1-h infusion 0.5-h infusion 
n 6 6 6 
Age (yrs) 27.7 ± 2.3 30.3 ± 8.0 31.0 ± 7.3 
Weight (kg) 60.3 ± 7.9 87.7 ± 14.8 82.5 ± 16.9 
Height (cm) 167.9 ± 7.7 167.9 ± 7.7 179.3 ± 10.5 
Gender (M:F) 5:1 5:1 6:0 
 
All data are presented as mean ± S.D. 
 
 
 
 
 
.
Table 2: Mean Pharmacokinetic Parameters of Taurultam 
 
Duration of 
infusion 
n AUC(0-24) 
 
AUC(0-ω) 
 
Cmax 
 
half life 
 
Tmax  
 
hr  hr*ug/mL hr*ug/mL ug/mL hr hr 
2 6 34.9 ± 9.6 35.7 ± 9.0 16.0 ± 4.5 1.1 ± 0.3 1.50 
1 5 37.3 ± 10.1   40.7 ± 11.2   32.0 ± 16.1 1.2 ± 0.7 0.75 
0.5 6 44.8 ± 9.8   51.8 ± 10.6   51.4 ± 12.2 2.1 ± 1.1 0.50 
All Groups  38.8 ± 9.8    42.9 ± 11.4   32.0 ± 17.9 1.5 ± 0.9   0.50* 
* = median     All data are presented as mean ± S.D. 
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Table 3: Mean Pharmacokinetic Parameters of Taurinamide 
 
Duration of 
infusion 
n AUC(0-24) 
 
AUC(0-ω) 
 
Cmax 
 
half life 
 
Tmax 
 
hr  hr*ug/mL hr*ug/mL ug/mL hr hr 
2 6 315.4 ± 46.5 356.5 ± 61.1 53.9 ± 10.8 6.9 ± 1.5 2.00 
1 5 233.9 ± 29.4 269.0 ± 35.3 59.4 ± 19.4 6.5 ± 1.4 1.00 
0.5 6 271.7 ± 61.4 310.3 ± 67.2 62.6 ± 16.8 6.7 ± 1.2 0.63 
All Groups  273.4 ± 55.8 312.7 ± 63.2 57.3 ± 15.3 6.7 ± 1.3   1.00* 
* = median   .   All data are presented as mean ± S.D. 
 
Figure 1: Metabolic disposition of taurolidine 
 
 
 
 
 
 Figure 2: Concentration time curves for taurultam (TRT) and taurinamide (TRM) following intravenous infusion of 
taurolidine 
 
 
 
 
Figure 2  Time-concentration relationship of the taurolidine metabolites taurultam and taurinamide in three intravenous infusion 
groups.  Panel (A) 2-, 1- and 0.5-h infusion groups for taurultam  (B) 2-, 1- and 0.5-h infusion groups for taurinamide.  All data were 
presented as mean ± S.D. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure Legend 
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Panel A, Figure 2 
TRT by Duration of Infusion
0 1 2 3 4 5 6
0
10
20
30
40
50
60
2 hr infusion
1 hr infusion
0.5 hr infusion
Time (hr)
C
o
n
c
e
n
t
r
a
t
i
o
n
 
(
µ
µ µ
µ
g
/
m
L
)
 23 
 
 
Panel B, Figure 2 
TRM by Duration of Infusion
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